Imara reports second quarter 2021 financial results and business highlights

Accelerated enrollment in phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
ELVN Ratings Summary
ELVN Quant Ranking